Mesoblast (NASDAQ:MESO) Trading 2.9% Higher – What’s Next?

Mesoblast Limited (NASDAQ:MESO) rose 2.9% during trading on Monday . The company traded as high as $12.49 and last traded at $12.47. Approximately 95,243 shares traded hands during trading, a decline of 75% from the average daily volume of 383,352 shares. The stock had previously closed at $12.11.

Analyst Ratings Changes

Several research firms recently weighed in on MESO. Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a report on Tuesday, March 4th. Piper Sandler restated an “overweight” rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Finally, Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Mesoblast has an average rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Stock Down 4.6 %

The company’s 50 day moving average is $16.09 and its 200 day moving average is $13.29. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Investors Weigh In On Mesoblast

A number of institutional investors have recently added to or reduced their stakes in MESO. Cubist Systematic Strategies LLC lifted its position in shares of Mesoblast by 241.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 35,191 shares of the company’s stock worth $697,000 after acquiring an additional 24,870 shares during the period. Bank of America Corp DE boosted its stake in Mesoblast by 1,503.3% during the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company’s stock worth $5,756,000 after buying an additional 272,595 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock valued at $51,000 after buying an additional 2,597 shares during the period. Tower Research Capital LLC TRC acquired a new position in shares of Mesoblast in the 4th quarter valued at $88,000. Finally, Jump Financial LLC bought a new position in shares of Mesoblast during the 4th quarter worth about $205,000. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.